The Challenge
Can large-scale proteomic data reveal the subtypes and shared mechanisms that drive neurodegenerative disease?
The lack of treatment and diagnostic options for neurodegenerative disorders remains a major barrier to care for more than 57 million people worldwide. The GNPC unites proteomic and clinical data at unprecedented scale to understand what drives these diseases — both shared and disease-specific— and to inform better diagnosis and treatment.
Our Approach
Launched in 2023, the GNPC is a first-of-its-kind public-private partnership uniting academic, government and industry researchers. It harmonizes proteomic data from dozens of cohorts into a single Harmonized Data Set on AD Workbench, pairing each proteomic profile with clinical and diagnostic data and analyzing both longitudinal and cross-sectional data to find mechanisms specific to and shared across diseases.
The world's largest dementia protein biomarker discovery effort.
Key Research Questions
01
Which protein signatures distinguish neurodegenerative disease subtypes?
02
Which protein signatures distinguish neurodegenerative disease subtypes?
03
Can proteogenomic analysis surface novel biomarkers and drug targets for earlier diagnosis?
Representative questions, not a comprehensive list.
Partners & Investigators
Founding Partners
Co-funders
Program Partners
Cohorts
ACE
ALLFTD
ALS TDI
Answer ALS
Banner
BarcelonaBeta
20+ international groups
Partner and funder lists are representative, not comprehensive.
Data & Tools
v1 Harmonized Data Set (HDS)
40,000+ samples from 20+ groups; ~300M protein measurements.
vMultiplatform HDS
The next iteration, in progress — broadening cohort and platform diversity.
AD Workbench
The secure cloud environment hosting GNPC data.
v1.0 HDS
Launched · public access
- 40,000+ samples
- ~300M protein measurements
vMultiplatform
In build · embargoed access
- ~45 cohorts
- ~50,000 individual samples
NNDC + India Consortium
Expanding
- Greater cohort diversity
- Cross-consortia data sharing
Publications & Resources
The Global Neurodegeneration Proteomics Consortium: Biomarker and Drug Target Discovery for common neurodegenerative diseases and aging
